{"id":"NCT02181413","sponsor":"Takeda","briefTitle":"A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant","officialTitle":"A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07-16","primaryCompletion":"2018-04-16","completion":"2023-09-08","firstPosted":"2014-07-04","resultsPosted":"2019-05-07","lastUpdate":"2024-11-19"},"enrollment":656,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma","Autologous Stem Cell Transplant"],"interventions":[{"type":"DRUG","name":"Ixazomib Citrate","otherNames":["MLN9708"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Ixazomib Citrate","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo, in participants with newly diagnosed multiple myeloma (NDMM) who have had a response (complete response \\[CR\\], very good partial response \\[VGPR\\], or partial response \\[PR\\]) to induction therapy followed by high-dose therapy (HDT) and autologous stem cell transplant (ASCT).","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)","effectByArm":[{"arm":"Placebo","deltaMin":21.3,"sd":null},{"arm":"Ixazomib Citrate","deltaMin":26.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":227,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Norway","Poland","Portugal","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["36130300","32613281","31880006","30545780"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":51,"n":259},"commonTop":["Diarrhoea","Nausea","Nasopharyngitis","Upper respiratory tract infection","Arthralgia"]}}